John Tsai

Executive Partner
Syncona Investment Limited

​

John is currently an Executive Partner at Syncona, a VC Company based out of London UK.  He is a member on the leadership team at Syncona that evaluates and makes decisions on new opportunities to strengthen the existing biotech portfolio.  In addition, he works across the portfolio companies to help advance the portfolio pipelines based on his 20+ years of experience in bringing innovative therapies to market across geographies and therapeutic areas.  Currently, John serves as the CEO of Forcefield Therapeutics focused in cardiovascular disease, the Chairperson for Purespring Therapeutics, a kidney disease company, and CMO for Mosaic Therapeutics, a targeted oncology company.
In addition, John currently serves as a non-executive director on the board of directors for Blueprint Medicines, a precision focused oncology therapeutic company, and also a non-executive director for Spur Therapeutics, a gene therapy company focused on neurological diseases.
Prior to Syncona, John was President, Global Drug Development and Chief Medical Officer at Novartis AG, where he led the Company's development portfolio spanning 160 new projects and 500 clinical trials as well as the team that secured global approvals for 15 new medicines including treatments using gene therapy, cell therapies, and new advanced platforms. Before joining Novartis in 2018, John served as Chief Medical Officer and Senior Vice President of Global Medical Affairs at Amgen Inc. and spent 11 years at Bristol-Myers Squibb Company where he held various senior positions within the Medical and Drug Development organizations. 
John holds a medical degree from the University of Louisville School of Medicine and a Bachelor of Science in Electrical Engineering from Washington University in St. Louis. He completed his residency at Kaiser Permanente in San Francisco, California, where he then served as a physician in internal medicine, Chief Resident and as a member of the hospital's faculty.

 

Speech title & Synopsis

Panel Discussion 1: BD & Licensing

as Moderator